The Global Transthyretin
Amyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran
(ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (Hereditary
Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild
Type), and by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies,
Retail Pharmacies, and Online Pharmacies) and by Geography (North America,
Latin America, Europe, Asia-Pacific, Middle East and Africa) is expected to be
valued at US$ 35.8 million in 2018 and is projected to exhibit a CAGR of 55.4%
over the forecast period (2018–2026).
Launch of novel therapies
indicated for the treatment of transthyretin amyloidosis is expected to propel
growth of the market. For instance, in October 2018, Alnylam Pharmaceuticals,
Inc. launched ONPATTRO (patisiran) in Germany. The drug is indicated for the
treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults
with stage 1 or stage 2 polyneuropathy. In October 2018, Ionis Pharmaceuticals,
Inc. and Akcea Therapeutics, Inc. received the U.S. Food and Drug
Administration (FDA) approval for its novel drug TEGSEDI (inotersen) indicated
for the treatment of polyneuropathy of hereditary transthyretin-mediated
amyloidosis in adults.
Key manufacturers in market have
their novel therapies under development pipeline and are expected to gain approval
in the near future. Presence of robust pipeline is also expected to be one the
major factors driving the market growth. For instance, in March 2018, Pfizer,
Inc. reported positive results from Phase 3 ATTR-ACT study of Tafamidis among
patients suffering from transthyretin cardiomyopathy
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/687
Browse 35 Market Data Tables and
43 Figures spread through 221 Pages and in-depth TOC on Global Transthyretin
Amyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran
(ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (Hereditary
Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild
Type), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and
Online Pharmacies) - Forecast to 2026
Key players in the market are
focused on strategic mergers and partnerships in order to enhance their market
share. For instance, In October 2018, Ionis Pharmaceuticals, Inc. and Akcea
Therapeutics, Inc. entered into distribution agreement with Accredo specialty
pharmacy, a subsidiary of Express Scripts to distribute TEGSEDI (inotersen)
subcutaneous injection for the treatment of polyneuropathy of hereditary
transthyretin-mediated (hATTR) amyloidosis in adults. In August 2018, Alnylam
Pharmaceuticals, Inc. partnered with US Bioservices, a specialty pharmacy and
part of AmerisourceBergen, to dispense ONPATTRO (patisiran) lipid complex
injection.
Transthyretin amyloidosis is a
rare disease and its symptoms are not easily identified. It is therefore,
diagnosed late, which in turn affects the course of action in terms of
treatment. According to the data published by The American Journal of Managed
Care in 2017, hereditary transthyretin-mediated (hATTR) amyloidosis affects
around 50,000 patients worldwide. However, the diagnosis rate of disease is very
low. According to the study published by Alnylam Pharmaceuticals, Inc., in
January 2018, the diagnosis rate of hATTR in the U.S. is around ~10-30%, which
is expected to be a major factor restraining growth of the market over the
forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/transthyretin-amyloidosis-treatment-market-687
Key Takeaways of the Global
Transthyretin Amyloidosis Treatment Market:
The global transthyretin
amyloidosis treatment market is expected to exhibit a CAGR of 4% over the
forecast period, owing to product launches by manufacturers such as Alnylam
Pharmaceuticals, Inc. and Ionis Therapeutics
North America is expected to hold
dominant position in the global transthyretin amyloidosis treatment market over
the forecast period, owing to approval and launch of new products in the
region. For instance, in June 2017, the U.S. Food and Drug Administration (FDA)
granted Fast Track designation to Pfizer Inc.’s Tafamidis, the company’s
investigational treatment therapy for Transthyretin Cardiomyopathy (TTR-CM).
Asia Pacific is expected to
witness significant growth in the market due increasing approvals of novel
therapies in the region. For instance, in March, 2018, the Ministry of Health
Labor and Welfare in Japan granted SAKIGAKE designation to Pfizer Inc.’s
Tafamidis, for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
However, no approved drugs are
available for the treatment of cardiomyopathy. Therefore, key players in the
market are could focus on this opportunity to receive approval for their drugs
for cardiomyopathy indication and can launch their drug in key region such as
the U.S. to enhance their market share.
Similar to cardiomyopathy, no
specifically approved drug is available for the treatment of wild-type
transthyretin amyloidosis. Therefore, key players could focus on this
opportunity to develop drugs for the treatment of wild type disease to gain
high revenue and market share.
Major players operating in the
global transthyretin amyloidosis treatment market include, Alnylam
Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline
Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation
Biotech, S.L.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/687
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-173
No comments:
Post a Comment